Potential conflict of interest: Dr. Guha received grants from Pfizer and Conatus.
Steatohepatitis/Metabolic Liver Disease
Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease†
Article first published online: 7 JAN 2013
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 57, Issue 1, pages 103–111, January 2013
How to Cite
Tanwar, S., Trembling, P. M., Guha, I. N., Parkes, J., Kaye, P., Burt, A. D., Ryder, S. D., Aithal, G. P., Day, C. P. and Rosenberg, W. M. (2013), Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology, 57: 103–111. doi: 10.1002/hep.26030
- Issue published online: 7 JAN 2013
- Article first published online: 7 JAN 2013
- Accepted manuscript online: 29 AUG 2012 03:23AM EST
- Manuscript Accepted: 3 AUG 2012
- Manuscript Received: 27 JUN 2012
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.